secwatch.observer — SEC 8-K summary
======================================

Issuer:     OptimizeRx Corp (OPRX)
CIK:        0001448431
Form:       8-K
Filed at:   2025-03-10T23:59:59+00:00
Accession:  0001213900-25-021923
Event type: leadership
Sentiment:  positive
Materiality: 0.75
Item codes: 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

OptimizeRx appoints Stephen Silvestro as CEO effective March 10, 2025
---------------------------------------------------------------------

- Stephen Silvestro, previously interim CEO and President, appointed permanent CEO as of March 10, 2025.
- Silvestro receives $500,000 annual base salary, target bonus of 80%, and $1.0M one-time equity grant.
- Silvestro joined OptimizeRx in 2019 as CCO; served as President from Oct 2023; prior roles at CCH Tagetik, Prognos Health, Decision Resources Group.
- Board conducted rigorous search with executive search firm; unanimous decision to appoint Silvestro, per Chair Lynn Vos.
- Silvestro aims to focus on customer centricity, recurring revenue model, and becoming a Rule of 40 company.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1448431/000121390025021923/0001213900-25-021923-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1448431/000121390025021923/ea0233702-8k_optimize.htm
  HTML page:      https://secwatch.observer/filing/0001213900-25-021923

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer